{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T12:37:17Z","timestamp":1699965437194},"reference-count":88,"publisher":"Informa Healthcare","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1517\/13543784.15.12.1555","type":"journal-article","created":{"date-parts":[[2006,11,16]],"date-time":"2006-11-16T02:10:42Z","timestamp":1163643042000},"page":"1555-1563","source":"Crossref","is-referenced-by-count":4,"title":["Experimental therapy in myelofibrosis with myeloid metaplasia"],"prefix":"10.1517","volume":"15","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"The University of Texas, Department of Leukemia, MD Anderson Cancer Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[{"name":"The University of Texas, Department of Leukemia, MD Anderson Cancer Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"The University of Texas, Department of Leukemia, MD Anderson Cancer Center, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","unstructured":"TEFFERI A: Myelofibrosis with myeloid metaplasia.N. Engl. J. Med.(2000) 342(17):1255-1265.","DOI":"10.1056\/NEJM200004273421706"},{"key":"CIT0002","doi-asserted-by":"crossref","unstructured":"JACOBSON RJ, SALO A, FIALKOW PJ: Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.Blood(1978) 51(2):189-194.","DOI":"10.1182\/blood.V51.2.189.bloodjournal512189"},{"key":"CIT0003","doi-asserted-by":"crossref","unstructured":"REEDER TL, BAILEY RJ, DEWALD GW, TEFFERI A: Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.Blood(2003) 101(5):1981-1983.","DOI":"10.1182\/blood-2002-07-2341"},{"key":"CIT0004","doi-asserted-by":"crossref","unstructured":"DUPRIEZ B, MOREL P, DEMORY JLetal.: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.Blood(1996) 88(3):1013-1018.","DOI":"10.1182\/blood.V88.3.1013.bloodjournal8831013"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"CERVANTES F, PEREIRA A, ESTEVE Jetal.: Identification of \u2018short-lived\u2019 and \u2018long-lived\u2019 patients at presentation of idiopathic myelofibrosis. Br. J. Haematol. (1997) 97(3):635-640.","DOI":"10.1046\/j.1365-2141.1997.782714.x"},{"key":"CIT0006","doi-asserted-by":"crossref","unstructured":"OKAMURA T, KINUKAWA N, NIHO Y, MIZOGUCHI H: Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int. J. Hematol. (2001) 73(2):194-198.","DOI":"10.1007\/BF02981937"},{"key":"CIT0007","doi-asserted-by":"crossref","unstructured":"CERVANTES F, TASSIES D, SALGADO Cetal.: Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. (1991) 85(3):124-127.","DOI":"10.1159\/000204873"},{"key":"CIT0008","doi-asserted-by":"crossref","unstructured":"DEEG HJ, GOOLEY TA, FLOWERS MEetal.: Allogeneic hematopoietic stem cell transplantation for myelofibrosis.Blood(2003) 102(12):3912-3918.","DOI":"10.1182\/blood-2003-06-1856"},{"key":"CIT0009","doi-asserted-by":"crossref","unstructured":"KRALOVICS R, PASSAMONTI F, BUSER ASetal.: A gain-of-function mutation of JAK2 in myeloproliferative disorders.N. Engl. J. Med.(2005) 352(17):1779-1790.","DOI":"10.1056\/NEJMoa051113"},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"BAXTER EJ, SCOTT LM, CAMPBELL PJetal.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet(2005) 365(9464):1054-1061.","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"JAMES C, UGO V, LE COUEDIC JPetal.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Nature(2005) 434(7037):1144-1148.","DOI":"10.1038\/nature03546"},{"key":"CIT0012","doi-asserted-by":"crossref","unstructured":"LEVINE RL, WADLEIGH M, COOLS Jetal.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 7(4):387-397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"ZHAO R, XING S, LI Zetal.: Identification of an acquired JAK2 mutation in polycythemia vera.J. Biol. Chem.(2005) 280(24):22788-22792.","DOI":"10.1074\/jbc.C500138200"},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"TEFFERI A, LASHO TL, SCHWAGER SMetal.: The JAK2V617Ftyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.Br. J. Haematol.(2005) 131(3):320-328.","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"CIT0015","doi-asserted-by":"crossref","unstructured":"LACOUT C, PISANI DF, TULLIEZ Metal.: JAK2V617Fexpression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.Blood(2006) 108(5):1652-1660.","DOI":"10.1182\/blood-2006-02-002030"},{"key":"CIT0016","doi-asserted-by":"crossref","unstructured":"WERNIG G, MERCHER T, OKABE Retal.: Expression of JAK2V617Fcauses a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.Blood(2006) 107(11):4274-4281.","DOI":"10.1182\/blood-2005-12-4824"},{"key":"CIT0017","volume-title":"PLoS Med","volume":"3","author":"PIKMAN","year":"2006"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"SCHMITT A, JOUAULT H, GUICHARD Jetal.: Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis.Blood(2000) 96(4):1342-1347.","DOI":"10.1182\/blood.V96.4.1342.h8001342_1342_1347"},{"key":"CIT0019","doi-asserted-by":"crossref","unstructured":"XU M, BRUNO E, CHAO Jetal.: Constitutive mobilization of CD34+cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases.Blood(2005) 105(11):4508-4515.","DOI":"10.1182\/blood-2004-08-3238"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"CHAGRAOUI H, KOMURA E, TULLIEZ Metal.: Prominent role of TGF-\u03b21in thrombopoietin-induced myelofibrosis in mice.Blood(2002) 100(10):3495-3503.","DOI":"10.1182\/blood-2002-04-1133"},{"key":"CIT0021","doi-asserted-by":"crossref","unstructured":"VILLEVAL JL, COHEN-SOLAL K, TULLIEZ Metal.: High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.Blood(1997) 90(11):4369-4383.","DOI":"10.1182\/blood.V90.11.4369.4369_4369_4383"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"VANNUCCHI AM, BIANCHI L, CELLAI Cetal.: Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1 (low) mice).Blood(2002) 100(4):1123-1132.","DOI":"10.1182\/blood-2002-06-1913"},{"key":"CIT0023","doi-asserted-by":"crossref","unstructured":"VANNUCCHI AM, BIANCHI L, PAOLETTI Fetal.: A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-\u03b21in the development of myelofibrosis.Blood(2005) 105(9):3493-3501.","DOI":"10.1182\/blood-2004-04-1320"},{"key":"CIT0024","doi-asserted-by":"crossref","unstructured":"TEFFERI A, MESA RA, SCHROEDER Getal.: Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia.Br. J. Haematol.(2001) 113(3):763-771.","DOI":"10.1046\/j.1365-2141.2001.02796.x"},{"key":"CIT0025","doi-asserted-by":"crossref","unstructured":"TEFFERI A, STRAND JJ, LASHO TLetal.: Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617Fand response to erythropoietin therapy.Cancer(2006) 106(8):1739-1743.","DOI":"10.1002\/cncr.21787"},{"key":"CIT0026","doi-asserted-by":"crossref","unstructured":"TEFFERI A, DINGLI D, LI CY, DEWALD GW: Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.Cancer(2005) 104(8):1656-1660.","DOI":"10.1002\/cncr.21358"},{"key":"CIT0027","doi-asserted-by":"crossref","unstructured":"DINGLI D, SCHWAGER SM, MESA RAetal.: Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.Cancer(2006) 106(9):1985-1989.","DOI":"10.1002\/cncr.21868"},{"key":"CIT0028","doi-asserted-by":"crossref","unstructured":"DINGLI D, GRAND FH, MAHAFFEY Vetal.: Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia.Br. J. Haematol.(2005) 130(2):229-232.","DOI":"10.1111\/j.1365-2141.2005.05593.x"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"UGO V, MARZAC C, TEYSSANDIER Ietal.: Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.Exp. Hematol.(2004) 32(2):179-187.","DOI":"10.1016\/j.exphem.2003.11.003"},{"key":"CIT0030","doi-asserted-by":"crossref","unstructured":"FADERL S, HARRIS D, VAN Qetal.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.Blood(2003) 102(2):630-637.","DOI":"10.1182\/blood-2002-06-1890"},{"key":"CIT0031","doi-asserted-by":"crossref","unstructured":"MEYDAN N, GRUNBERGER T, DADI Hetal.: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.Nature(1996) 379(6566):645-648.","DOI":"10.1038\/379645a0"},{"key":"CIT0032","unstructured":"PRIEBE W, FOKT I, SZYMANSKI Setal.: Design, synthesis and structure\u2013activity relationships of novel Jak2\/STAT3 signaling Inhibitors. Proc. Am. Assoc. Cancer Res. (2006) 47:LB-298 (Abstract)."},{"key":"CIT0033","unstructured":"MADDEN T, KAZEROONI R, MYER Jetal.: The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2\/STAT3 pathway. Proc. Am. Assoc. Cancer Res. (2006) 47:4853 (Abstract)."},{"key":"CIT0034","unstructured":"KAPURIA V, BARTHOLOMEUSZ G, PRIEBE Wetal.: WP1130, a small molecular weight compound, inhibits JAK2-STAT3 signaling through a unique degradation mechanism. Proc. Am. Assoc. Cancer Res. (2006) 47:3012 (Abstract)."},{"key":"CIT0035","unstructured":"BARTHOLOMEUSZ G, DONATO N, PRIEBE Wetal.: Degradation of c-Myc by WP1130 through activation of a novel proteasomal-dependent pathway. Proc. Am. Assoc. Cancer Res. (2006) 47:3022 (Abstract)."},{"key":"CIT0036","unstructured":"KUPFERMAN M, ZHOU G, ZHAO Metal.: A novel inhibitor of STAT3 signaling in head and neck squamous cell carcinoma. Proc. Am. Assoc. Cancer Res. (2006) 47:2413 (Abstract)."},{"key":"CIT0037","doi-asserted-by":"crossref","unstructured":"HARRINGTON EA, BEBBINGTON D, MOORE Jetal.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growthinvivo. Nat. Med. (2004) 10(3):262-267.","DOI":"10.1038\/nm1003"},{"key":"CIT0038","doi-asserted-by":"crossref","unstructured":"SCHAFER PH, GANDHI AK, LOVELAND MAetal.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.J. Pharmacol. Exp. Ther.(2003) 305(3):1222-1232.","DOI":"10.1124\/jpet.102.048496"},{"key":"CIT0039","doi-asserted-by":"crossref","unstructured":"MULLER GW, CHEN R, HUANG SYetal.: Amino-substituted thalidomide analogs: potent inhibitors of TNF-\u03b1 production. Bioorg. Med. Chem. Lett. (1999) 9(11):1625-1630.","DOI":"10.1016\/S0960-894X(99)00250-4"},{"key":"CIT0040","doi-asserted-by":"crossref","unstructured":"DREDGE K, HORSFALL R, ROBINSON SPetal.: Orally administered lenalidomide (CC-5013) is anti-angiogenicinvivoand inhibits endothelial cell migration and Akt phosphorylationinvitro.Microvasc. Res.(2005) 69(1-2):56-63.","DOI":"10.1016\/j.mvr.2005.01.002"},{"key":"CIT0041","doi-asserted-by":"crossref","unstructured":"TEFFERI A, CORTES J, VERSTOVSEK Setal.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia.Blood(2006) 108(4):1158-1164.","DOI":"10.1182\/blood-2006-02-004572"},{"key":"CIT0042","doi-asserted-by":"crossref","unstructured":"MESA RA, ELLIOTT MA, SCHROEDER G, TEFFERI A: Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.Mayo Clin. Proc.(2004) 79(7):883-889.","DOI":"10.4065\/79.7.883"},{"key":"CIT0043","doi-asserted-by":"crossref","unstructured":"SCHEY SA, FIELDS P, BARTLETT JBetal.: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.J. Clin. Oncol.(2004) 22(16):3269-3276.","DOI":"10.1200\/JCO.2004.10.052"},{"key":"CIT0044","unstructured":"PRESTA LG, CHEN H, O\u2019CONNOR SJetal.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res.(1997) 57(20):4593-4599."},{"key":"CIT0045","doi-asserted-by":"crossref","unstructured":"CARDONES AR, BANEZ LL: VEGF inhibitors in cancer therapy. Curr. Pharm. Des. (2006) 12(3):387-394.","DOI":"10.2174\/138161206775201910"},{"key":"CIT0046","doi-asserted-by":"crossref","unstructured":"O\u2019FARRELL AM, ABRAMS TJ, YUEN HAetal.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activityinvitroandinvivo.Blood(2003) 101(9):3597-3605.","DOI":"10.1182\/blood-2002-07-2307"},{"key":"CIT0047","unstructured":"MENDEL DB, LAIRD AD, XIN Xetal.:Invivoantitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship.Clin. Cancer Res. (2003) 9(1):327-337."},{"key":"CIT0048","doi-asserted-by":"crossref","unstructured":"FIEDLER W, SERVE H, DOHNER Hetal.: A Phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.Blood(2005) 105(3):986-993.","DOI":"10.1182\/blood-2004-05-1846"},{"key":"CIT0049","unstructured":"WOOD JM, BOLD G, BUCHDUNGER Eetal.: PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.Cancer Res.(2000) 60(8):2178-2189."},{"key":"CIT0050","unstructured":"GILES F, COOPER, MA, SILVERMAN, Letal.: Phase II study of PTK787\/ZK222584 (PTK\/ZK), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia.Blood(2003) 102(11):3431 (Abstract)."},{"key":"CIT0051","doi-asserted-by":"crossref","unstructured":"GILES FJ, COOPER MA, SILVERMAN Letal.: Phase II study of SU5416 \u2013 a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor in patients with refractory myeloproliferative diseases.Cancer(2003) 97(8):1920-1928.","DOI":"10.1002\/cncr.11315"},{"key":"CIT0052","doi-asserted-by":"crossref","unstructured":"HASSELBACH H: SU6668 in idiopathic myelofibrosis \u2013 a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis.Med. Hypotheses(2003) 61(2):244-247.","DOI":"10.1016\/S0306-9877(03)00155-5"},{"key":"CIT0053","doi-asserted-by":"crossref","unstructured":"KONNER J, DUPONT J: Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin. Colorectal Cancer (2004) 4(Suppl. 2):S81-S85.","DOI":"10.3816\/CCC.2004.s.013"},{"key":"CIT0054","doi-asserted-by":"crossref","unstructured":"SCHIFFELERS RM, STORM G: ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opin. Drug Deliv. (2006) 3(3):445-454.","DOI":"10.1517\/17425247.3.3.445"},{"key":"CIT0055","doi-asserted-by":"crossref","unstructured":"YINGLING JM, BLANCHARD KL, SAWYER JS: Development of TGF-\u03b2 signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. (2004) 3(12):1011-1022.","DOI":"10.1038\/nrd1580"},{"key":"CIT0056","doi-asserted-by":"crossref","unstructured":"SCHLINGENSIEPEN K, BISCHOF A, EGGER Tetal.: The TGF-\u03b21antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies.Proc. Am. Soc. Clin. Oncol.(2004) 23:3132 (Abstract).","DOI":"10.1200\/jco.2004.22.14_suppl.3132"},{"key":"CIT0057","doi-asserted-by":"crossref","unstructured":"SAWYER JS, BEIGHT DW, BRITT KSetal.: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-\u03b2 type I receptor kinase domain.Bioorg. Med. Chem.Lett(2004) 14(13):3581-3584.","DOI":"10.1002\/chin.200441142"},{"key":"CIT0058","doi-asserted-by":"crossref","unstructured":"GELLIBERT F, WOOLVEN J, FOUCHET MHetal.: Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-\u03b2 type I receptor inhibitors.J. Med. Chem.(2004) 47(18):4494-4506.","DOI":"10.1021\/jm0400247"},{"key":"CIT0059","doi-asserted-by":"crossref","unstructured":"CALLAHAN JF, BURGESS JL, FORNWALD JAetal.: Identification of novel inhibitors of the transforming growth factor \u03b21(TGF-\u03b21) type 1 receptor (ALK5).J. Med. Chem.(2002) 45(5):999-1001.","DOI":"10.1021\/jm010493y"},{"key":"CIT0060","doi-asserted-by":"crossref","unstructured":"UHL M, AULWURM S, WISCHHUSEN Jetal.: SD-208, a novel transforming growth factor \u03b2 receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cellsinvitroandinvivo.Cancer Res.(2004) 64(21):7954-7961.","DOI":"10.1158\/0008-5472.CAN-04-1013"},{"key":"CIT0061","doi-asserted-by":"crossref","unstructured":"MESA RA, TEFFERI A, ELLIOTT MAetal.: A Phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.Br. J. Haematol.(2001) 114(1):111-113.","DOI":"10.1046\/j.1365-2141.2001.02883.x"},{"key":"CIT0062","doi-asserted-by":"crossref","unstructured":"REILLY JT, WILSON G, BARNETT D, WATMORE A, POTTER A: Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis.Br. J. Haematol.(1994) 88(3):575-581.","DOI":"10.1111\/j.1365-2141.1994.tb05076.x"},{"key":"CIT0063","doi-asserted-by":"crossref","unstructured":"BEAUPRE DM, KURZROCK R: RAS and leukemia: from basic mechanisms to gene-directed therapy.J. Clin. Oncol.(1999) 17(3):1071-1079.","DOI":"10.1200\/JCO.1999.17.3.1071"},{"key":"CIT0064","doi-asserted-by":"crossref","unstructured":"DU W, LEBOWITZ PF, PRENDERGAST GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.Mol. Cell. Biol.(1999) 19(3):1831-1840.","DOI":"10.1128\/MCB.19.3.1831"},{"key":"CIT0065","doi-asserted-by":"crossref","unstructured":"ASHAR HR, JAMES L, GRAY Ketal.: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.J. Biol. Chem.(2000) 275(39):30451-30457.","DOI":"10.1074\/jbc.M003469200"},{"key":"CIT0066","doi-asserted-by":"crossref","unstructured":"CORTES J, ALBITAR M, THOMAS Detal.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.Blood(2003) 101(5):1692-1697.","DOI":"10.1182\/blood-2002-07-1973"},{"key":"CIT0067","doi-asserted-by":"crossref","unstructured":"MESA R, CAMOIRANO JK, GEYER SMetal.: A Phase II consortium (P2C) trial of R115777 (tipifarnib) in myelofibrosis with myeloid metaplasia.Blood(2004) 104(11):1509 (Abstract).","DOI":"10.1182\/blood.V104.11.1509.1509"},{"key":"CIT0068","doi-asserted-by":"crossref","unstructured":"KANTARJIAN H, SAWYERS C, HOCHHAUS Aetal.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N. Engl. J. Med.(2002) 346(9):645-652.","DOI":"10.1056\/NEJMoa011573"},{"key":"CIT0069","doi-asserted-by":"crossref","unstructured":"KVASNICKA HM, THIELE J, STAIB Petal.: Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.Blood(2004) 103(9):3549-3551.","DOI":"10.1182\/blood-2003-08-2734"},{"key":"CIT0070","doi-asserted-by":"crossref","unstructured":"BEHAM-SCHMID C, APFELBECK U, SILL Hetal.: Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.Blood(2002) 99(1):381-383.","DOI":"10.1182\/blood.V99.1.381"},{"key":"CIT0071","unstructured":"GISSLINGER H, GISSLINGER H, KEES M: Imatinib mesylate in chronic idiopathic myelofibrosis, a Phase II trial.Blood(2002) 100(11):3161 (Abstract)."},{"key":"CIT0072","doi-asserted-by":"crossref","unstructured":"TEFFERI A, MESA RA, GRAY LAetal.: Phase II trial of imatinib mesylate in myelofibrosis with myeloid metaplasia.Blood(2002) 99(10):3854-3856.","DOI":"10.1182\/blood-2001-12-0154"},{"key":"CIT0073","doi-asserted-by":"crossref","unstructured":"CORTES J, GILES F, O\u2019BRIEN Setal.: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.Cancer(2003) 97(11):2760-2766.","DOI":"10.1002\/cncr.11416"},{"key":"CIT0074","unstructured":"ODENIKE O, HOVING K, SHER D: Phase II study of imatinib mesylate (IM) in myelofibrosis with myeloid metaplasia (MMM). Proc. Am. Soc. Clin. Oncol. (2003) 22:2354 (Abstract)."},{"key":"CIT0075","doi-asserted-by":"crossref","unstructured":"HASSELBALCH HC, BJERRUM OW, JENSEN BAetal.: Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.Am. J. Hematol.(2003) 74(4):238-242.","DOI":"10.1002\/ajh.10431"},{"key":"CIT0076","unstructured":"DEANGELO D, SOIFFER RJ, GALINSKY Ietal.: Imatinib mesylate (Gleevec) for patients with chronic idiopathic myelofibrosis (CIM): a Phase II trial.Blood(2003) 102(11):502 (Abstract)."},{"key":"CIT0077","doi-asserted-by":"crossref","unstructured":"LE BOUSSE-KERDILES M, DESTEKE C, GUERTON Betal.: Glivec\/STI571 treatment stimulates megakaryopoiesis and normalizes PDGF receptor \u03b2 kinase expression in thrombocytopenic patients with myeloid metaplasia with myelofibrosis.Blood(2005) 106(11):2599 (Abstract).","DOI":"10.1182\/blood.V106.11.2599.2599"},{"key":"CIT0078","doi-asserted-by":"crossref","unstructured":"LOMBARDO LJ, LEE FY, CHEN Petal.: Discovery ofN-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.J. Med. Chem.(2004) 47(27):6658-6661.","DOI":"10.1021\/jm049486a"},{"key":"CIT0079","doi-asserted-by":"crossref","unstructured":"BAYLIN SB, HERMAN JG, GRAFF JR, VERTINO PM, ISSA JP: Alterations in DNA methylation: a fundamental aspect of neoplasia.Adv. Cancer Res. (1998) 72:141-196.","DOI":"10.1016\/S0065-230X(08)60702-2"},{"key":"CIT0080","doi-asserted-by":"crossref","unstructured":"KUMAGAI T, TEFFERI A, JONES L, KOEFFLER HP: Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia.Leuk. Res.(2005) 29(5):511-515.","DOI":"10.1016\/j.leukres.2004.11.002"},{"key":"CIT0081","unstructured":"MARTYRE MC: Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr. Hematol. Rep. (2003) 2(3):257-263."},{"key":"CIT0082","doi-asserted-by":"crossref","unstructured":"WANG JC, CHEN W, NALLUSAMY S, CHEN C, NOVETSKY AD: Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation.Br. J. Haematol.(2002) 116(3):582-586.","DOI":"10.1046\/j.0007-1048.2001.03319.x"},{"key":"CIT0083","doi-asserted-by":"crossref","unstructured":"ISSA JP, GHARIBYAN V, CORTES Jetal.: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.J. Clin. Oncol.(2005) 23(17):3948-3956.","DOI":"10.1200\/JCO.2005.11.981"},{"key":"CIT0084","doi-asserted-by":"crossref","unstructured":"ISSA JP, KANTARJIAN H: Azacitidine.Nat. Rev. Drug Discov.(2005):S6-S7 (Supplement).","DOI":"10.1038\/nrd1726"},{"key":"CIT0085","doi-asserted-by":"crossref","unstructured":"KOMURA E, TONETTI C, PENARD-LACRONIQUE Vetal.: Role for the nuclear factor \u03baB pathway in transforming growth factor-\u03b21production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression.Cancer Res.(2005) 65(8):3281-3289.","DOI":"10.1158\/0008-5472.CAN-04-2339"},{"key":"CIT0086","doi-asserted-by":"crossref","unstructured":"RAMESHWAR P, NARAYANAN R, QIAN Jetal.: NF-\u03ba B as a central mediator in the induction of TGF-\u03b2 in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis.J. Immunol.(2000) 165(4):2271-2277.","DOI":"10.4049\/jimmunol.165.4.2271"},{"key":"CIT0087","doi-asserted-by":"crossref","unstructured":"WAGNER-BALLON O, GASTINNE T, TULLIEZ Metal.: Proteasome inhibitor bortezomib can inhibit bone marrow fibrosis development in a murine model of myelofibrosis.Blood(2005) 106(11):2582 (Abstract).","DOI":"10.1182\/blood.V106.11.2582.2582"},{"key":"CIT0088","doi-asserted-by":"crossref","unstructured":"O\u2019BRIEN S, KIPPS TJ, FADERL Setal.: A Phase I trial of the small molecule pan-Bcl-2 family inhibitor GX15-070 administered intravenously (iv) every 3 weeks to patients with previously treated chronic lymphocytic leukemia (CLL).Blood(2005) 106(11):446 (Abstract).","DOI":"10.1182\/blood.V106.11.446.446"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.15.12.1555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T19:27:25Z","timestamp":1628105245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.15.12.1555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,15]]},"references-count":88,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2006,11,15]]},"published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1517\/13543784.15.12.1555"],"URL":"https:\/\/doi.org\/10.1517\/13543784.15.12.1555","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,15]]}}}